Fewer VCs Showing a Taste for ObesityNo matter the impending FDA decisions on obesity drugs, many VCs say the approval process is too daunting—and costly—to investByTom York1 May 2012•6 mins readJavaScript is required to read this article. Please enable it in your browser and reload the page.Managers
